India orders unapproved Covid vaccines to vaccinate its people. The decision comes in the middle of the deadly second wave in the South Asian country. The vaccine has no name and is undergoing a phase 3 trial. Biological E is in the making of the vaccine to provide the government with a large supply. The vaccine is successful in the past 2 trials. Also, the results are promising following the trials of phase 2. India has signed for $206 million for the vaccine jab. However, the vaccine didn’t receive emergency approval for use. The decision will help the struggling country to fight off the pandemic.
India is a country with a total population spanning 1.4 billion. There are nearly 220 million people who have had the 1st dose of the vaccine. However, that sum still represents only 15% of the country’s population. The shortage in the availability of vaccines is hampering the process on a large scale. Although the number of cases is no longer increasing. But, the vaccination pace needs to improve in order to minimize public health risks.
The number of cases in India is reducing. India is now recording 100,000 cases a day which is significantly lower than a month before. However, experts believe that the figures are still underestimated. The current government is widely subject to criticism following the availability of vaccines. Currently, India has 3 vaccines, two from the local sources and Sputnik V from Moscow. India is also using local vaccines, Covishield and Covaxin. India orders 300 million (Not Approved) doses of the Covid-19 vaccine from Biological E. This new vaccine will soon be available in a couple of months for people.
